Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light-Based imaging may spot High-Risk preeclampsia early

NCT ID NCT06912477

Diagnosis Sponsor: Heidelberg University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study tests whether a non-invasive imaging technique called hyperspectral imaging can help predict how preeclampsia will progress in pregnant women. Preeclampsia is a serious condition that can harm both mother and baby, and it is linked to problems in the tiny blood vessels. Researchers will use the imaging to measure blood flow in the skin, along with blood samples, to see if these markers can forecast outcomes like how soon delivery is needed or if severe complications occur. The goal is to find a simple, safe way to identify women who need closer monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hyperspectral imaging, a non-invasive imaging technique that measures blood flow in the skin, combined with blood samples
What this could lead to
If it works, this could give doctors a simple, non-invasive way to predict which women with preeclampsia are at highest risk, allowing earlier and more targeted care.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change care yet. The imaging technique is new in this context, and results may not be conclusive or generalizable to all skin types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 385 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who are admitted to the Department of obstetrics at Heidelberg University Hospital

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * singleton pregnancies * Age ≥ 18 years * Patient's ability to provide consent * written informed consent Exclusion Criteria: * Lack of consent * Language barrier * Dark to very dark skin type * Severe fetal chromosomal/genetic/structural anomalies * Laboratory changes in LDH, creatinine, or platelets due to other causes (e.g., isolated thrombocytopenia, e.g., immune thrombocytopenia, carcinoma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertensive disorder of pregnancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertension, pregnancy-induced hypertensive disorder preeclampsia Toxemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertensive disorder of pregnancy Preeclampsia (PE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Heidelberg University Hospital, Department of Gynecology and Obstetrics

    RECRUITING

    Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.